“Ospemifene: less venous thrombosis than other selective estrogen receptor modulators in postmenopausal women with vulvo vaginal atrophy”. Menopause27 (8): 846–847. (August 2020). doi:10.1097/GME.0000000000001600. PMID32576803.
“ERAAs for menopause treatment: Welcome the 'designer estrogens'”. Cleve Clin J Med84 (6): 463–470. (June 2017). doi:10.3949/ccjm.84a.15140. PMID28628428.
“Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice”. The New England Journal of Medicine348 (7): 618–29. (Feb 2003). doi:10.1056/NEJMra022219. PMID12584371.
“Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast”. Post Reproductive Health21 (3): 112–21. (Sep 2015). doi:10.1177/2053369115599090. PMID26289836.
Bryant, Henry U. (2008). “Chapter 41 – The Pharmacology of Selective Estrogen Receptor Modulators”. Principles of Bone Biology. pp. 887–919. doi:10.1016/B978-0-12-373884-4.00058-6
“The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia”. Fertil. Steril.91 (4 Suppl): 1427–30. (April 2009). doi:10.1016/j.fertnstert.2008.06.002. PMID18692782.
“The effect of selective estrogen receptor modulators on parameters of the hypothalamic-pituitary-gonadal axis”. Ann. N. Y. Acad. Sci.949: 251–8. (December 2001). doi:10.1111/j.1749-6632.2001.tb04029.x. PMID11795360.
“Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause”. Expert Opin Drug Metab Toxicol12 (10): 1233–46. (October 2016). doi:10.1080/17425255.2016.1218847. PMID27476551.
“A double-blind, randomized, ascending, multiple-dose study of bazedoxifene in healthy postmenopausal women”. Clin Pharmacol Drug Dev3 (4): 262–9. (July 2014). doi:10.1002/cpdd.102. PMID27128831.
Trost, Landon W.; Khera, Mohit (2014). “Alternative Treatment Modalities for the Hypogonadal Patient”. Current Urology Reports15 (7). doi:10.1007/s11934-014-0417-2. ISSN1527-2737.
“Panning for SNuRMs: using cofactor profiling for the rational discovery of selective nuclear receptor modulators”. Drug Discovery Today12 (19–20): 860–9. (Oct 2007). doi:10.1016/j.drudis.2007.07.025. PMID17933688.
“Structure-based approach for the discovery of novel selective estrogen receptor modulators”. Current Medicinal Chemistry18 (8): 1188–94. (2011). doi:10.2174/092986711795029645. PMID21291367.
“Development of subtype-selective oestrogen receptor-based therapeutics”. Nature Reviews. Drug Discovery10 (10): 778–92. (Oct 2011). doi:10.1038/nrd3551. PMID21921919.
“Reflections on the discovery and significance of estrogen receptor beta”. Endocrine Reviews26 (3): 465–78. (May 2005). doi:10.1210/er.2004-0027. PMID15857973.
“Discovery of estrogen receptor modulators: a review of virtual screening and SAR efforts”. Expert Opinion on Drug Discovery5 (1): 21–31. (Jan 2010). doi:10.1517/17460440903490395. PMID22823969.
“Molecular basis of agonism and antagonism in the oestrogen receptor”. Nature389 (6652): 753–8. (1997). doi:10.1038/39645. PMID9338790.
“The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen”. Cell95 (7): 927–37. (1998). doi:10.1016/S0092-8674(00)81717-1. PMID9875847.
“Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs)”. Current Medicinal Chemistry14 (11): 1249–61. (2007). doi:10.2174/092986707780598023. PMID17504144.
“Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance”. Mutation Research591 (1–2): 247–63. (Dec 2005). doi:10.1016/j.mrfmmm.2005.02.028. PMID16083919.
“Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens”. Chemical Research in Toxicology14 (3): 280–94. (Mar 2001). doi:10.1021/tx000208y. PMID11258977.
“Tamoxifen: important considerations of a multi-functional compound with organ-specific properties”. Cancer Treatment Reviews33 (2): 91–100. (Apr 2007). doi:10.1016/j.ctrv.2006.09.008. PMID17178195.]
“Multiple targeting by the antitumor drug tamoxifen: a structure-activity study”. Current Medicinal Chemistry. Anti-Cancer Agents4 (6): 491–508. (Nov 2004). doi:10.2174/1568011043352696. PMID15579015.
“New Highly Stereoselective Synthesis of (Z)-4-Hydroxytamoxifen and (Z)-4-Hydroxytoremifene via McMurry Reaction”. The Journal of Organic Chemistry61 (11): 3890–3893. (May 1996). doi:10.1021/jo952279l. PMID11667248.
“Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents”. Journal of Medicinal Chemistry46 (7): 1081–111. (Mar 2003). doi:10.1021/jm020450x. PMID12646017.
“Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis”. Expert Opinion on Pharmacotherapy10 (8): 1377–85. (Jun 2009). doi:10.1517/14656560902980228. PMID19445558.
“Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy”. Expert Opinion on Investigational Drugs15 (3): 293–305. (Mar 2006). doi:10.1517/13543784.15.3.293. PMID16503765.
“Ospemifene: less venous thrombosis than other selective estrogen receptor modulators in postmenopausal women with vulvo vaginal atrophy”. Menopause27 (8): 846–847. (August 2020). doi:10.1097/GME.0000000000001600. PMID32576803.
“ERAAs for menopause treatment: Welcome the 'designer estrogens'”. Cleve Clin J Med84 (6): 463–470. (June 2017). doi:10.3949/ccjm.84a.15140. PMID28628428.
“Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice”. The New England Journal of Medicine348 (7): 618–29. (Feb 2003). doi:10.1056/NEJMra022219. PMID12584371.
“Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast”. Post Reproductive Health21 (3): 112–21. (Sep 2015). doi:10.1177/2053369115599090. PMID26289836.
“The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia”. Fertil. Steril.91 (4 Suppl): 1427–30. (April 2009). doi:10.1016/j.fertnstert.2008.06.002. PMID18692782.
“The effect of selective estrogen receptor modulators on parameters of the hypothalamic-pituitary-gonadal axis”. Ann. N. Y. Acad. Sci.949: 251–8. (December 2001). doi:10.1111/j.1749-6632.2001.tb04029.x. PMID11795360.
“Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause”. Expert Opin Drug Metab Toxicol12 (10): 1233–46. (October 2016). doi:10.1080/17425255.2016.1218847. PMID27476551.
“A double-blind, randomized, ascending, multiple-dose study of bazedoxifene in healthy postmenopausal women”. Clin Pharmacol Drug Dev3 (4): 262–9. (July 2014). doi:10.1002/cpdd.102. PMID27128831.
“Panning for SNuRMs: using cofactor profiling for the rational discovery of selective nuclear receptor modulators”. Drug Discovery Today12 (19–20): 860–9. (Oct 2007). doi:10.1016/j.drudis.2007.07.025. PMID17933688.
“Structure-based approach for the discovery of novel selective estrogen receptor modulators”. Current Medicinal Chemistry18 (8): 1188–94. (2011). doi:10.2174/092986711795029645. PMID21291367.
“Development of subtype-selective oestrogen receptor-based therapeutics”. Nature Reviews. Drug Discovery10 (10): 778–92. (Oct 2011). doi:10.1038/nrd3551. PMID21921919.
“Reflections on the discovery and significance of estrogen receptor beta”. Endocrine Reviews26 (3): 465–78. (May 2005). doi:10.1210/er.2004-0027. PMID15857973.
“Discovery of estrogen receptor modulators: a review of virtual screening and SAR efforts”. Expert Opinion on Drug Discovery5 (1): 21–31. (Jan 2010). doi:10.1517/17460440903490395. PMID22823969.
“Molecular basis of agonism and antagonism in the oestrogen receptor”. Nature389 (6652): 753–8. (1997). doi:10.1038/39645. PMID9338790.
“The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen”. Cell95 (7): 927–37. (1998). doi:10.1016/S0092-8674(00)81717-1. PMID9875847.
“Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs)”. Current Medicinal Chemistry14 (11): 1249–61. (2007). doi:10.2174/092986707780598023. PMID17504144.
“Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance”. Mutation Research591 (1–2): 247–63. (Dec 2005). doi:10.1016/j.mrfmmm.2005.02.028. PMID16083919.
“Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens”. Chemical Research in Toxicology14 (3): 280–94. (Mar 2001). doi:10.1021/tx000208y. PMID11258977.
“The estrogen receptor: a model for molecular medicine”. Clinical Cancer Research9 (6): 1980–9. (Jun 2003). PMID12796359.
“Tamoxifen: important considerations of a multi-functional compound with organ-specific properties”. Cancer Treatment Reviews33 (2): 91–100. (Apr 2007). doi:10.1016/j.ctrv.2006.09.008. PMID17178195.]
“Multiple targeting by the antitumor drug tamoxifen: a structure-activity study”. Current Medicinal Chemistry. Anti-Cancer Agents4 (6): 491–508. (Nov 2004). doi:10.2174/1568011043352696. PMID15579015.
“New Highly Stereoselective Synthesis of (Z)-4-Hydroxytamoxifen and (Z)-4-Hydroxytoremifene via McMurry Reaction”. The Journal of Organic Chemistry61 (11): 3890–3893. (May 1996). doi:10.1021/jo952279l. PMID11667248.
“Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents”. Journal of Medicinal Chemistry46 (7): 1081–111. (Mar 2003). doi:10.1021/jm020450x. PMID12646017.
“Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis”. Expert Opinion on Pharmacotherapy10 (8): 1377–85. (Jun 2009). doi:10.1517/14656560902980228. PMID19445558.
“Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy”. Expert Opinion on Investigational Drugs15 (3): 293–305. (Mar 2006). doi:10.1517/13543784.15.3.293. PMID16503765.
